Form 4: Perspective Therapeutics CFO Acquires Stock Options

Juan Graham, CFO of Perspective Therapeutics, Inc., reports the acquisition of stock options.

Summary

• On January 6, 2025, Juan Graham, the Chief Financial Officer of Perspective Therapeutics, Inc., acquired stock options to purchase 400,000 shares of common stock.
• The exercise price of these options is $3.53 per share.
• The options vest over a four-year period, starting with one-fourth vesting on January 6, 2026, and the remainder vesting ratably over the following 36 months, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting confidence in the company's future performance. The sentiment is neutral to positive.

Positives

• The acquisition of stock options by the CFO could align his interests with those of the shareholders, incentivizing him to work towards increasing the company's value.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen typically use stock options as part of their compensation strategy to incentivize long-term performance.
• The vesting schedule of four years with ratable vesting after the first year is also a common practice.

Stakeholder Impact

• The stock option grant could positively impact shareholders by aligning the CFO's interests with the company's long-term success.

Key Dates